Clinical Trial

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

Study acronym: EPICS-V
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Long-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-29
notable Trial sites expanded: 0 -> 3 locations 2026-07-29
Trial Details
NCT Number NCT07216235
Lead Sponsor Zydus Therapeutics Inc.
Conditions Primary Biliary Cholangitis
Enrollment 386 participants
Start Date 2026-03-24
Primary Completion 2032-11 (estimated)
Study Completion 2032-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-04